This trial is active, not recruiting.

Condition ergogenic effects of salbutamol in healthy males
Treatments salbutamol, placebo
Sponsor Bispebjerg Hospital
Collaborator University of Copenhagen
Start date August 2011
End date August 2012
Trial size 20 participants
Trial identifier NCT01415596, SALMUS2011


Many athletes use beta2-agonists as treatment of airway hyperresponsiveness during exercise. High dose beta2-agonists may have an ergogenic effect on exercise performance. We hypotheis that the beta2-agonist, salbutamol, taken in high doses can improve muscle power and recovery during exercise in well-trained athletes.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
(Placebo Comparator)
(Active Comparator)

Primary Outcomes

Muscle power
time frame:

Secondary Outcomes

Muscle recovery
time frame:

Eligibility Criteria

Male participants from 18 years up to 45 years old.

Inclusion Criteria: - Males - age 18-45 - training frequency > 10 hrs/wk - informed consent Exclusion Criteria: - smoker or former smoker - chronic diseases, as well as asthma - allergy to the study drugs - intake of any form of medicin or inhibited drugs during the study - use of beta2-agonist 14 days before the intervention

Additional Information

Official title The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males
Trial information was received from ClinicalTrials.gov and was last updated in August 2011.
Information provided to ClinicalTrials.gov by Bispebjerg Hospital.